IMUNON
@imunon.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
IMUNON's Company Logos
IMUNON's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#1275B3
Denim
18, 117, 179
203, 82, 39
90, 35, 0, 30
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#61442B
Quincy
97, 68, 43
28, 39, 27
0, 30, 56, 62
About IMUNON
IMUNON is a clinical-stage biotechnology company dedicated to developing revolutionary treatments that harness the body's immune system. With a focus on advancing a portfolio of innovative therapies, IMUNON aims to provide safe, effective, and durable responses against a wide range of human diseases. The company utilizes two platform technologies: TheraPlas® for immunotherapies and anti-cancer nucleic acid-based therapies, and PlaCCine for nucleic acid vaccines targeting infectious diseases and cancer.
IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy in Phase II development for advanced ovarian cancer. By instructing the body to produce powerful tumor-fighting molecules like interleukin-12 (IL-12) and interferon gamma (IFN-γ), IMNN-001 offers a localized and long-lasting treatment solution. Additionally, IMUNON is conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate for SARS-CoV-2, showcasing the potential of their PlaCCine platform.
Operating independently of viral vectors or devices, IMUNON's platform technologies rely on novel synthetic delivery systems for nucleic acid delivery. The company is committed to pushing the boundaries of plasmid DNA technology to better serve patients with challenging-to-treat conditions. With a dedication to scientific advancement and patient-centric solutions, IMUNON is paving the way for groundbreaking immune system-based therapies
Related Brands
Tags
DNA-based therapeutics
Immuno-oncology
Nucleic acid vaccine platforms
Non-viral DNA delivery
